BAK Fundamental Analysis - BRASKEM SA-CLASS A- ADR

Fundamental Rating

BAK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 82 industry peers in the Chemicals industry. Both the profitability and financial health of BAK have multiple concerns. While showing a medium growth rate, BAK is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

BAK had negative earnings in the past year.

BAK had a negative operating cash flow in the past year.

BAK had negative earnings in 4 of the past 5 years.

BAK had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -6.36%, BAK is doing worse than 75.61% of the companies in the same industry.

BAK's Return On Invested Capital of 0.56% is on the low side compared to the rest of the industry. BAK is outperformed by 78.05% of its industry peers.

		Industry Rank	Sector Rank
ROA	-6.36%
ROE	N/A
ROIC	0.56%

ROA(3y)-5.51%

ROA(5y)-1.84%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BAK's Operating Margin of 0.60% is on the low side compared to the rest of the industry. BAK is outperformed by 78.05% of its industry peers.

BAK's Operating Margin has declined in the last couple of years.

Looking at the Gross Margin, with a value of 6.52%, BAK is doing worse than 87.80% of the companies in the same industry.

In the last couple of years the Gross Margin of BAK has declined.

		Industry Rank	Sector Rank
OM	0.6%
PM (TTM)	N/A
GM	6.52%

OM growth 3Y-60.34%

OM growth 5Y-26.07%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-36.57%

GM growth 5Y-9.41%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BAK is destroying value.

The number of shares outstanding for BAK remains at a similar level compared to 1 year ago.

BAK has about the same amout of shares outstanding than it did 5 years ago.

The debt/assets ratio for BAK is higher compared to a year ago.

2.2 Solvency

BAK has an Altman-Z score of 0.77. This is a bad value and indicates that BAK is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of 0.77, BAK is doing worse than 80.49% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	0.77

ROIC/WACC0.1

WACC5.55%

2.3 Liquidity

A Current Ratio of 1.21 indicates that BAK should not have too much problems paying its short term obligations.

Looking at the Current ratio, with a value of 1.21, BAK is doing worse than 86.59% of the companies in the same industry.

A Quick Ratio of 0.68 indicates that BAK may have some problems paying its short term obligations.

With a Quick ratio value of 0.68, BAK is not doing good in the industry: 87.80% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.21
Quick Ratio	0.68

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BAK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.92%, which is quite impressive.

Looking at the last year, BAK shows a quite strong growth in Revenue. The Revenue has grown by 9.70% in the last year.

BAK shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.15% yearly.

EPS 1Y (TTM)26.92%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%92%

Revenue 1Y (TTM)9.7%

Revenue growth 3Y-9.84%

Revenue growth 5Y8.15%

Sales Q2Q%-18.65%

3.2 Future

The Earnings Per Share is expected to grow by 24.66% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 3.09% on average over the next years.

EPS Next Y81.16%

EPS Next 2Y32.08%

EPS Next 3Y24.66%

EPS Next 5YN/A

Revenue Next Year-6.52%

Revenue Next 2Y0.48%

Revenue Next 3Y3.09%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BAK. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BAK. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as BAK.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	13.26

4.3 Compensation for Growth

BAK's earnings are expected to grow with 24.66% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y32.08%

EPS Next 3Y24.66%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BAK does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BRASKEM SA-CLASS A- ADR

NYSE:BAK (12/8/2025, 8:04:00 PM)

2.91

-0.01 (-0.34%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)11-11 2025-11-11/bmo

Earnings (Next)02-24 2026-02-24/bmo

Inst Owners19.96%

Inst Owner Change-42.1%

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap1.16B

Revenue(TTM)77.41B

Net Income(TTM)-5.81B

Analysts50.67

Price Target4.64 (59.45%)

Short Float %2.29%

Short Ratio1.7

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0

Dividend Growth(5Y)-61.09%

DP-0.02%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)77.08%

Min EPS beat(2)64.59%

Max EPS beat(2)89.58%

EPS beat(4)2

Avg EPS beat(4)-292.98%

Min EPS beat(4)-870.87%

Max EPS beat(4)89.58%

EPS beat(8)2

Avg EPS beat(8)-200.87%

EPS beat(12)3

Avg EPS beat(12)-141.89%

EPS beat(16)4

Avg EPS beat(16)-120.57%

Revenue beat(2)0

Avg Revenue beat(2)-9.32%

Min Revenue beat(2)-10.48%

Max Revenue beat(2)-8.16%

Revenue beat(4)0

Avg Revenue beat(4)-6.86%

Min Revenue beat(4)-10.48%

Max Revenue beat(4)-1.01%

Revenue beat(8)0

Avg Revenue beat(8)-4.75%

Revenue beat(12)1

Avg Revenue beat(12)-3.68%

Revenue beat(16)2

Avg Revenue beat(16)-3.02%

PT rev (1m)-4.75%

PT rev (3m)-17.03%

EPS NQ rev (1m)0%

EPS NQ rev (3m)13.95%

EPS NY rev (1m)14.17%

EPS NY rev (3m)7.62%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-12.96%

Revenue NY rev (1m)-1.31%

Revenue NY rev (3m)-5.51%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.08
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	13.26

EPS(TTM)-2.46

EYN/A

EPS(NY)-1.34

Fwd EYN/A

FCF(TTM)-2.67

FCFYN/A

OCF(TTM)-1.2

OCFYN/A

SpS36.01

BVpS-1.76

TBVpS-3.25

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-6.36%
ROE	N/A
ROCE	0.71%
ROIC	0.56%
ROICexc	0.56%
ROICexgc	0.59%
OM	0.6%
PM (TTM)	N/A
GM	6.52%
FCFM	N/A

ROA(3y)-5.51%

ROA(5y)-1.84%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3Y-67.54%

ROICexgc growth 5Y-28.26%

ROICexc growth 3Y-67.47%

ROICexc growth 5Y-28%

OM growth 3Y-60.34%

OM growth 5Y-26.07%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-36.57%

GM growth 5Y-9.41%

F-Score3

Asset Turnover0.85

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	11.38
Cap/Depr	65.27%
Cap/Sales	4.08%
Interest Coverage	0.1
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.21
Quick Ratio	0.68
Altman-Z	0.77

F-Score3

WACC5.55%

ROIC/WACC0.1

Cap/Depr(3y)88.47%

Cap/Depr(5y)83.1%

Cap/Sales(3y)5.43%

Cap/Sales(5y)4.85%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)26.92%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%92%

EPS Next Y81.16%

EPS Next 2Y32.08%

EPS Next 3Y24.66%

EPS Next 5YN/A

Revenue 1Y (TTM)9.7%

Revenue growth 3Y-9.84%

Revenue growth 5Y8.15%

Sales Q2Q%-18.65%

Revenue Next Year-6.52%

Revenue Next 2Y0.48%

Revenue Next 3Y3.09%

Revenue Next 5YN/A

EBIT growth 1Y374.38%

EBIT growth 3Y-64.24%

EBIT growth 5Y-20.05%

EBIT Next Year201.32%

EBIT Next 3Y92.73%

EBIT Next 5YN/A

FCF growth 1Y-736.57%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-158.55%

OCF growth 3Y-45.19%

OCF growth 5Y1.46%

BRASKEM SA-CLASS A- ADR / BAK FAQ

What is the ChartMill fundamental rating of BRASKEM SA-CLASS A- ADR (BAK) stock?

ChartMill assigns a fundamental rating of 2 / 10 to BAK.

What is the valuation status for BAK stock?

ChartMill assigns a valuation rating of 1 / 10 to BRASKEM SA-CLASS A- ADR (BAK). This can be considered as Overvalued.

What is the profitability of BAK stock?

BRASKEM SA-CLASS A- ADR (BAK) has a profitability rating of 1 / 10.

What is the financial health of BRASKEM SA-CLASS A- ADR (BAK) stock?

The financial health rating of BRASKEM SA-CLASS A- ADR (BAK) is 1 / 10.

BRASKEM SA-CLASS A- ADR (BAK) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

BRASKEM SA-CLASS A- ADR / BAK FAQ

What is the ChartMill fundamental rating of BRASKEM SA-CLASS A- ADR (BAK) stock?

What is the valuation status for BAK stock?

What is the profitability of BAK stock?

What is the financial health of BRASKEM SA-CLASS A- ADR (BAK) stock?